A Phase 1 interventional study of insulin degludec and placebo in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-15.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies testing insulin degludec in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. insulin degludec · Diabetes Mellitus.
Among the 103 studies testing insulin degludec in Diabetes Mellitus, this one is the 77th largest by enrollment, is one of 3 that started in 2006, is one of 42 in phase 1, and was the 68th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 103 studies testing insulin degludec in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 145 across the 103 interventional studies. Of the 101 that completed or were terminated, 55 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 103 have an industry lead sponsor. The 7 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
642 studies in Diabetes Mellitus by Novo Nordisk A/S: 2 open now, 3 under way, 1 of them phase 3. Of 636 finished, 163 (26%) have results posted.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 382nd largest by enrollment of the 494 interventional ones that give a count, is one of 53 that started in 2006, is one of 206 in phase 1, and was the 480th registered.
Novo Nordisk A/S’s Diabetes Mellitus studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 103 studies testing insulin degludec in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 642 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability and pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) characteristics of insulin degludec (insulin 454) and insulin degludec/insulin aspart (IDegAsp) 50 - formerly SIAM), both explorative formulations, not similar to the proposed commercial formulation, in healthy male Japanese subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec · Drug: placebo
Drug: insulin degludec · Drug: placebo
Drug: insulin degludec · Drug: placebo
Drug: placebo · Drug: insulin degludec/insulin aspart 50
Single dose administered subcutaneously (s.c., under the skin).
Administered subcutaneously (s.c., under the skin)
Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
Frequency of adverse events (AEs)
Time frame: From dosing visit and until follow-up 7-21 days after last dosing visit
Area under the serum insulin concentration curve
Time frame: 0-96 hours after dosing
Area under the glucose infusion rate curve
Time frame: 0-24 hours after dosing
The record gives a start of Dec 2006, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec